Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Beyond Air reports interim data results for LungFit GO pilot study » 08:10
10/20/21
10/20
08:10
10/20/21
08:10
XAIR

Beyond Air

$9.72 /

-0.905 (-8.52%)

Beyond Air announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XAIR Beyond Air
$9.72 /

-0.905 (-8.52%)

XAIR Beyond Air
$9.72 /

-0.905 (-8.52%)

04/28/21
Fly Intel: Top five analyst initiations
04/28/21 Truist
Beyond Air initiated with a Buy at Truist
04/28/21 Truist
Beyond Air initiated with a Buy at Truist
XAIR Beyond Air
$9.72 /

-0.905 (-8.52%)

XAIR Beyond Air
$9.72 /

-0.905 (-8.52%)

Friday
Recommendations
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald » 07:07
10/15/21
10/15
07:07
10/15/21
07:07
INCY

Incyte

$65.76 /

+1.53 (+2.38%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Alethia Young lowered the firm's price target on Incyte to $79 from $104 and keeps a Neutral rating on the shares. Young was "somewhat surprised" by the FDA adding a black box class warning to Opzelura, and the analyst is more cautious about a potentially slower uptake related to the class labelling, Young tells investors in a research note.

ShowHide Related Items >><<
INCY Incyte
$65.76 /

+1.53 (+2.38%)

INCY Incyte
$65.76 /

+1.53 (+2.38%)

10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
09/27/21 Stifel
Incyte's in-licensing of axatilimab 'a strategically sound move,' says Stifel
09/23/21 Gordon Haskett
Gordon Haskett compares Incyte to Alexion before Astra buyout
INCY Incyte
$65.76 /

+1.53 (+2.38%)

INCY Incyte
$65.76 /

+1.53 (+2.38%)

INCY Incyte
$65.76 /

+1.53 (+2.38%)

Over a week ago
Periodicals
Amazon shopping for long-range Boeing, Airbus cargo plans, Bloomberg reports » 12:54
10/13/21
10/13
12:54
10/13/21
12:54
AMZN

Amazon.com

$3,273.57 /

+24.68 (+0.76%)

, BA

Boeing

$221.65 /

-1.885 (-0.84%)

, EADSY

Airbus

$32.57 /

-0.1 (-0.31%)

, UPS

UPS

$182.88 /

+0.89 (+0.49%)

, FDX

FedEx

$223.79 /

+2.42 (+1.09%)

Amazon.com (AMZN) is…

Amazon.com (AMZN) is shopping for used long-range Boeing (BA) and Airbus (EADSY) cargo planes, Matt Day and Julie Johnsson of Bloomberg report, citing people familiar with the matter. Amazon is in the market for refurbished cargo versions of Boeing's 777-300ER and Airbus's A330-300 wide-body aircraft, sources told Bloomberg. Converted Boeing 777s would let Amazon directly import products from China and other countries, the sources said, which would step up the company's competition with UPS (UPS) and FedEx (FDX).

ShowHide Related Items >><<
UPS UPS
$182.88 /

+0.89 (+0.49%)

FDX FedEx
$223.79 /

+2.42 (+1.09%)

EADSY Airbus
$32.57 /

-0.1 (-0.31%)

BA Boeing
$221.65 /

-1.885 (-0.84%)

AMZN Amazon.com
$3,273.57 /

+24.68 (+0.76%)

AMZN Amazon.com
$3,273.57 /

+24.68 (+0.76%)

10/13/21 Baird
Amazon.com weakness would be a buying opportunity, says Baird
10/12/21 JPMorgan
JPMorgan says Alphabet 'clearly the most liked' mega-cap internet stock
10/11/21 Loop Capital
Bed Bath & Beyond price target lowered to $14 from $18 at Loop Capital
10/07/21 Stephens
Comcast-branded Smart TV Launch in U.S. 'likely imminent,' says Stephens
BA Boeing
$221.65 /

-1.885 (-0.84%)

10/13/21 JPMorgan
Boeing Q3 delivery report highlights challenges, says JPMorgan
09/29/21
Fly Intel: Top five analyst upgrades
09/29/21 Bernstein
Boeing upgraded to Outperform from Market Perform at Bernstein
09/15/21 Susquehanna
Boeing upcoming catalysts should move shares higher, says Susquehanna
EADSY Airbus
$32.57 /

-0.1 (-0.31%)

10/05/21 Credit Suisse
Airbus price target raised to EUR 138 from EUR 137 at Credit Suisse
09/29/21 Bernstein
Airbus upgraded to Outperform from Market Perform at Bernstein
08/04/21 Deutsche Bank
Airbus price target raised to EUR 131 from EUR 122 at Deutsche Bank
UPS UPS
$182.88 /

+0.89 (+0.49%)

09/28/21
Fly Intel: Top five analyst initiations
09/28/21 Evercore ISI
UPS initiated with an Outperform at Evercore ISI
08/05/21 Morgan Stanley
Amazon continues toward competing with parcel incumbents, says Morgan Stanley
07/28/21 Credit Suisse
UPS price target lowered to $240 from $261 at Credit Suisse
FDX FedEx
$223.79 /

+2.42 (+1.09%)

10/08/21 Citi
FedEx earnings estimates cut below guidance at Citi
10/06/21 Cowen
FedEx price target lowered to $283 from $297 at Cowen
09/23/21 Stifel
FedEx setup doesn't warrant 'trough valuation,' time to buy, says Stifel
09/23/21 Argus
FedEx price target lowered to $270 from $330 at Argus
UPS UPS
$182.88 /

+0.89 (+0.49%)

FDX FedEx
$223.79 /

+2.42 (+1.09%)

EADSY Airbus
$32.57 /

-0.1 (-0.31%)

BA Boeing
$221.65 /

-1.885 (-0.84%)

AMZN Amazon.com
$3,273.57 /

+24.68 (+0.76%)

UPS UPS
$182.88 /

+0.89 (+0.49%)

FDX FedEx
$223.79 /

+2.42 (+1.09%)

EADSY Airbus
$32.57 /

-0.1 (-0.31%)

BA Boeing
$221.65 /

-1.885 (-0.84%)

AMZN Amazon.com
$3,273.57 /

+24.68 (+0.76%)

UPS UPS
$182.88 /

+0.89 (+0.49%)

FDX FedEx
$223.79 /

+2.42 (+1.09%)

EADSY Airbus
$32.57 /

-0.1 (-0.31%)

BA Boeing
$221.65 /

-1.885 (-0.84%)

AMZN Amazon.com
$3,273.57 /

+24.68 (+0.76%)

UPS UPS
$182.88 /

+0.89 (+0.49%)

FDX FedEx
$223.79 /

+2.42 (+1.09%)

BA Boeing
$221.65 /

-1.885 (-0.84%)

AMZN Amazon.com
$3,273.57 /

+24.68 (+0.76%)

Hot Stocks
Katapult collaborates with Adobe to give consumers more ways to pay » 09:06
10/11/21
10/11
09:06
10/11/21
09:06
KPLT

Katapult

$4.55 /

-0.145 (-3.09%)

, ADBE

Adobe

$576.59 /

-1.96 (-0.34%)

Katapult (KPLT) announced…

Katapult (KPLT) announced it has become an Accelerate partner in the Adobe (ADBE) Exchange Program. Adobe Commerce, powered by Magento, is an application for brands of all sizes and supports B2B, B2C, and hybrid use cases across more than 20 industries. Katapult's lease-purchase solution is available as an extension in the payment category of the Magento Marketplace and integrates with online platforms. As an Accelerate partner, Katapult and Adobe will engage in enhanced collaboration. Becoming an Accelerate partner means that Katapult's merchants utilizing Adobe Commerce or Magento Open Source will receive support and access to real-time data and partner offerings. "Upgrading our partnership with Adobe to the Accelerate tier furthers Katapult's goals of expanding our footprint in the fintech space. We are excited to add more value through our technology to merchants using Adobe Commerce and Magento Open Source," says Rolando De Gracia, Chief Commercial Officer of Katapult.

ShowHide Related Items >><<
KPLT Katapult
$4.55 /

-0.145 (-3.09%)

ADBE Adobe
$576.59 /

-1.96 (-0.34%)

KPLT Katapult
$4.55 /

-0.145 (-3.09%)

10/05/21 Cantor Fitzgerald
Katapult initiated with a Neutral at Cantor Fitzgerald
09/03/21 KeyBanc
Katapult well positioned to benefit from new partnerships, says KeyBanc
08/12/21 Loop Capital
Katapult price target lowered to $7 from $12 at Loop Capital
07/19/21 Loop Capital
Katapult upgraded to Buy from Hold at Loop Capital
ADBE Adobe
$576.59 /

-1.96 (-0.34%)

10/01/21 Wells Fargo
Wells says Applied Materials CFO exit 'surprising,' but doesn't change thesis
09/24/21 Piper Sandler
Salesforce upgraded to Overweight from Neutral at Piper Sandler
09/22/21 Oppenheimer
Adobe price target raised to $680 from $600 at Oppenheimer
09/22/21 JPMorgan
Adobe price target raised to $680 from $660 at JPMorgan
KPLT Katapult
$4.55 /

-0.145 (-3.09%)

ADBE Adobe
$576.59 /

-1.96 (-0.34%)

ADBE Adobe
$576.59 /

-1.96 (-0.34%)

KPLT Katapult
$4.55 /

-0.145 (-3.09%)

ADBE Adobe
$576.59 /

-1.96 (-0.34%)

KPLT Katapult
$4.55 /

-0.145 (-3.09%)

ADBE Adobe
$576.59 /

-1.96 (-0.34%)

Hot Stocks
Hyatt opens IL Tornabuoni Hotel in Florence » 05:11
10/11/21
10/11
05:11
10/11/21
05:11
H

Hyatt

$83.78 /

+1.975 (+2.41%)

Hyatt announced the…

Hyatt announced the opening of IL Tornabuoni Hotel in Florence. The 62-bedroom former palace signifies the debut of The Unbound Collection by Hyatt brand in Italy.

ShowHide Related Items >><<
H Hyatt
$83.78 /

+1.975 (+2.41%)

H Hyatt
$83.78 /

+1.975 (+2.41%)

10/05/21 Loop Capital
Hyatt initiated with a Hold at Loop Capital
09/27/21
Fly Intel: Top five analyst downgrades
09/27/21 BofA
Hyatt cut to Underperform at BofA after real estate conference
09/27/21 BofA
Hyatt downgraded to Underperform from Neutral at BofA
H Hyatt
$83.78 /

+1.975 (+2.41%)

  • 23
    Sep
H Hyatt
$83.78 /

+1.975 (+2.41%)

H Hyatt
$83.78 /

+1.975 (+2.41%)

On The Fly
Short Report: Amplify Energy, Lordstown Motors shorts jump amid headwinds » 13:20
10/09/21
10/09
13:20
10/09/21
13:20
AMPY

Amplify Energy

$3.43 /

+0.03 (+0.88%)

, RIDE

Lordstown Motors

$4.89 /

-0.155 (-3.08%)

, FIZZ

National Beverage

$55.07 /

-0.44 (-0.79%)

, M

Macy's

$22.76 /

+0.24 (+1.07%)

, NYT

New York Times

$53.03 /

+0.75 (+1.43%)

, AVTE

Aerovate Therapeutics

$20.29 /

+2.92 (+16.81%)

, CRCT

Cricut

$27.03 /

+0.39 (+1.46%)

, SFIX

Stitch Fix

$34.46 /

-2.4499 (-6.64%)

Welcome to this week’s…

ShowHide Related Items >><<
SFIX Stitch Fix
$34.46 /

-2.4499 (-6.64%)

RIDE Lordstown Motors
$4.89 /

-0.155 (-3.08%)

NYT New York Times
$53.03 /

+0.75 (+1.43%)

M Macy's
$22.76 /

+0.24 (+1.07%)

CRCT Cricut
$27.03 /

+0.39 (+1.46%)

AVTE Aerovate Therapeutics
$20.29 /

+2.92 (+16.81%)

AMPY Amplify Energy
$3.43 /

+0.03 (+0.88%)

AMPY Amplify Energy
$3.43 /

+0.03 (+0.88%)

10/04/21 Roth Capital
Amplify Energy downgraded to Neutral from Buy at Roth Capital
12/15/20 Roth Capital
Amplify Energy upgraded to Buy on deleveraging opportunity at Roth Capital
12/15/20 Roth Capital
Amplify Energy upgraded to Buy from Neutral at Roth Capital
RIDE Lordstown Motors
$4.89 /

-0.155 (-3.08%)

10/05/21
Fly Intel: Top five analyst downgrades
10/04/21 Morgan Stanley
Lordstown Motors downgraded to Underweight from Equal Weight at Morgan Stanley
10/04/21 RBC Capital
Lordstown Motors price target raised to $5 from $1 at RBC Capital
09/30/21 Morgan Stanley
Lordstown Motors reinstated with an Equal Weight at Morgan Stanley
FIZZ National Beverage
$55.07 /

-0.44 (-0.79%)

02/03/21 UBS
National Beverage downgraded to Sell from Neutral at UBS
10/20/20
Fly Intel: Top five analyst upgrades
10/20/20 Jefferies
National Beverage upgraded to Hold on better La Croix market share at Jefferies
10/20/20 Jefferies
National Beverage upgraded to Hold from Underperform at Jefferies
M Macy's
$22.76 /

+0.24 (+1.07%)

09/28/21
Fly Intel: Top five analyst upgrades
09/28/21 Gordon Haskett
Macy's upgraded to Buy from Hold at Gordon Haskett
09/09/21 Cowen
Cowen upgrades Macy's to Outperform, sees 'American icon reinvented'
09/09/21
Fly Intel: Top five analyst upgrades
NYT New York Times
$53.03 /

+0.75 (+1.43%)

05/06/21 JPMorgan
New York Times shares may be range-bound near term, says JPMorgan
03/18/21 Guggenheim
Guggenheim upgrades News Corp. to Buy, sees 'significant value' to be unlocked
11/09/20 Evercore ISI
New York Times upgraded to Outperform from In Line at Evercore ISI
10/27/20 JPMorgan
New York Times selloff brings attractive entry point, says JPMorgan
AVTE Aerovate Therapeutics
$20.29 /

+2.92 (+16.81%)

07/26/21 Cowen
Aerovate Therapeutics initiated with an Outperform at Cowen
07/26/21 Evercore ISI
Aerovate Therapeutics initiated with an Outperform at Evercore ISI
07/26/21 Jefferies
Jefferies starts Aerovate at Buy, sees potential for significant upside
07/26/21 Wedbush
Wedbush bullish on Aerovate Therapeutics, initiates with an Outperform
CRCT Cricut
$27.03 /

+0.39 (+1.46%)

10/01/21 Barclays
Cricut downgraded to Underweight from Equal Weight at Barclays
08/17/21 Barclays
Cricut downgraded to Equal Weight from Overweight at Barclays
08/13/21
Fly Intel: Top five analyst downgrades
08/13/21 Goldman Sachs
Cricut downgraded to Neutral from Buy at Goldman Sachs
SFIX Stitch Fix
$34.46 /

-2.4499 (-6.64%)

10/04/21 Wedbush
Wedbush sees several key tailwinds for footwear and apparel sector
10/04/21 Wedbush
Stitch Fix initiated with a Neutral at Wedbush
09/22/21 MKM Partners
MKM Partners warns that FY22 will not be inflection year for Stitch Fix
09/22/21 Canaccord
Stitch Fix price target lowered to $65 from $76 at Canaccord
SFIX Stitch Fix
$34.46 /

-2.4499 (-6.64%)

RIDE Lordstown Motors
$4.89 /

-0.155 (-3.08%)

NYT New York Times
$53.03 /

+0.75 (+1.43%)

M Macy's
$22.76 /

+0.24 (+1.07%)

FIZZ National Beverage
$55.07 /

-0.44 (-0.79%)

CRCT Cricut
$27.03 /

+0.39 (+1.46%)

AVTE Aerovate Therapeutics
$20.29 /

+2.92 (+16.81%)

  • 30
    Jun
  • 25
    Mar
  • 11
    Dec
SFIX Stitch Fix
$34.46 /

-2.4499 (-6.64%)

RIDE Lordstown Motors
$4.89 /

-0.155 (-3.08%)

NYT New York Times
$53.03 /

+0.75 (+1.43%)

M Macy's
$22.76 /

+0.24 (+1.07%)

AMPY Amplify Energy
$3.43 /

+0.03 (+0.88%)

SFIX Stitch Fix
$34.46 /

-2.4499 (-6.64%)

RIDE Lordstown Motors
$4.89 /

-0.155 (-3.08%)

NYT New York Times
$53.03 /

+0.75 (+1.43%)

M Macy's
$22.76 /

+0.24 (+1.07%)

FIZZ National Beverage
$55.07 /

-0.44 (-0.79%)

CRCT Cricut
$27.03 /

+0.39 (+1.46%)

AVTE Aerovate Therapeutics
$20.29 /

+2.92 (+16.81%)

AMPY Amplify Energy
$3.43 /

+0.03 (+0.88%)

SFIX Stitch Fix
$34.46 /

-2.4499 (-6.64%)

RIDE Lordstown Motors
$4.89 /

-0.155 (-3.08%)

M Macy's
$22.76 /

+0.24 (+1.07%)

CRCT Cricut
$27.03 /

+0.39 (+1.46%)

AMPY Amplify Energy
$3.43 /

+0.03 (+0.88%)

Hot Stocks
Bluebird Bio provides update on planned business separation » 16:57
10/08/21
10/08
16:57
10/08/21
16:57
BLUE

Bluebird Bio

$19.11 /

+0.24 (+1.27%)

Bluebird bio announced…

Bluebird bio announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the U.S. SEC. This Form 10 reflects bluebird bio's plans for a tax-free spin-off of its oncology programs and portfolio into 2seventy bio as a publicly traded company. The spin-off is on track to be completed by early November. bluebird bio also announced the appointment of Najoh Tita-Reid and Sarah Glickman to the bluebird bio board of directors. Upon effectiveness of the Form 10, Glickman will also be a member of the board of directors of 2seventy bio and will step down from the bluebird bio board of directors upon completion of the spin-off. Upon separation, bluebird bio plans to distribute 100% of the outstanding shares of 2seventy bio common stock to bluebird's shareholders in a 3:1 ratio. For every three shares of bluebird bio stock, current shareholders will receive one share of 2seventy bio stock. The company anticipates that its cash, cash equivalents and marketable securities balance at separation will be approximately $1.0B, inclusive of proceeds from the recent sale of the company's manufacturing facility in North Carolina and its private placement equity financing. bluebird bio expects to fund 2seventy bio with approximately $480M in cash upon separation, with the balance to be retained by bluebird bio. Together with existing and emerging sources of revenue and other anticipated cash inflows, which includes the potential sale of priority review vouchers that would be issued with anticipated U.S. regulatory approvals of BLAs for bluebird's therapies in beta-thalassemia and cerebral adrenoleukodystrophy, the company expects its cash, cash equivalents and marketable securities balance will be sufficient to fund operations for bluebird bio and 2seventy bio into 2023 under current business plans.

ShowHide Related Items >><<
BLUE Bluebird Bio
$19.11 /

+0.24 (+1.27%)

BLUE Bluebird Bio
$19.11 /

+0.24 (+1.27%)

10/08/21 BofA
Allogene Therapeutics price target lowered to $32 from $41 at BofA
09/30/21 Spin-Off Research
Bluebird Bio initiated with a Hold at Spin-Off Research
09/22/21 Mizuho
Bluebird Bio price target lowered to $23 from $29 at Mizuho
08/10/21
Fly Intel: Top five analyst downgrades
BLUE Bluebird Bio
$19.11 /

+0.24 (+1.27%)

BLUE Bluebird Bio
$19.11 /

+0.24 (+1.27%)

Hot Stocks
Summit Therapeutics appoints Kenneth Clark to board of directors » 08:31
10/08/21
10/08
08:31
10/08/21
08:31
SMMT

Summit Therapeutics

$5.02 /

+0.145 (+2.98%)

Summit Therapeutics…

Summit Therapeutics announced that Kenneth Clark, JD, has been appointed to our Board of Directors, effective immediately. Mr. Clark is currently a partner at Wilson Sonsini Goodrich & Rosati based out of the firm's Palo Alto, CA, office. In conjunction with Mr. Clark's appointment, Ramses Erdtmann has agreed to make his Summit Board seat available.

ShowHide Related Items >><<
SMMT Summit Therapeutics
$5.02 /

+0.145 (+2.98%)

SMMT Summit Therapeutics
$5.02 /

+0.145 (+2.98%)

11/18/20 H.C. Wainwright
Summit Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
SMMT Summit Therapeutics
$5.02 /

+0.145 (+2.98%)

SMMT Summit Therapeutics
$5.02 /

+0.145 (+2.98%)

Recommendations
Allogene Therapeutics price target lowered to $32 from $41 at BofA » 07:47
10/08/21
10/08
07:47
10/08/21
07:47
ALLO

Allogene Therapeutics

$24.37 /

+0.37 (+1.54%)

, BLUE

Bluebird Bio

$18.87 /

+0.35 (+1.89%)

BofA analyst Jason…

BofA analyst Jason Gerberry lowered the firm's price target on Allogene Therapeutics (ALLO) to $32 from $41 after the company announced a clinical hold was placed on both of its clinical stage allogeneic CAR-T programs after a single patient report involving a chromosomal abnormality in ALLO-501A CAR-T cells in the patient. The clinical hold "creates a layer of regulatory uncertainty," said Gerberry, who noted that it took Bluebird Bio (BLUE) about four months to get a clinical hold removed for its gene therapy for blood disorders to determine whether vector integration promoted cancer. The analyst, who keeps a Buy rating on the shares, said his new target factors in lower clinical probabilities of success for both Allogene programs and reduced assumptions for '501 share versus marketed auto CAR-T's.

ShowHide Related Items >><<
BLUE Bluebird Bio
$18.87 /

+0.35 (+1.89%)

ALLO Allogene Therapeutics
$24.37 /

+0.37 (+1.54%)

ALLO Allogene Therapeutics
$24.37 /

+0.37 (+1.54%)

10/08/21 Stifel
Allogene Therapeutics downgraded to Hold from Buy at Stifel
10/08/21 Baird
Baird cuts Cellectis to Neutral after partner Allogene's clinical hold
10/08/21 Oppenheimer
Allogene Therapeutics price target lowered to $40 from $44 at Oppenheimer
10/08/21 RBC Capital
Allogene Therapeutics price target lowered to $45 from $55 at RBC Capital
BLUE Bluebird Bio
$18.87 /

+0.35 (+1.89%)

09/30/21 Spin-Off Research
Bluebird Bio initiated with a Hold at Spin-Off Research
09/22/21 Mizuho
Bluebird Bio price target lowered to $23 from $29 at Mizuho
08/10/21
Fly Intel: Top five analyst downgrades
08/10/21 BMO Capital
Bluebird Bio price target lowered to $21 from $29 at BMO Capital
BLUE Bluebird Bio
$18.87 /

+0.35 (+1.89%)

ALLO Allogene Therapeutics
$24.37 /

+0.37 (+1.54%)

BLUE Bluebird Bio
$18.87 /

+0.35 (+1.89%)

ALLO Allogene Therapeutics
$24.37 /

+0.37 (+1.54%)

Recommendations
FedEx earnings estimates cut below guidance at Citi » 06:50
10/08/21
10/08
06:50
10/08/21
06:50
FDX

FedEx

$222.88 /

-1.32 (-0.59%)

Citi analyst Christian…

Citi analyst Christian Wetherbee lowered his second half of fiscal 2022 earnings estimates for FedEx as he believes it is likely that labor and operational costs from Q1 linger past Q2. He cut his fiscal 2022 earnings per share estimate to $18.85 from $19.75, below the low end of management's $19.75-$21.00 target range. Wetherbee keeps a Buy rating on FedEx with a $300 price target.

ShowHide Related Items >><<
FDX FedEx
$222.88 /

-1.32 (-0.59%)

FDX FedEx
$222.88 /

-1.32 (-0.59%)

10/06/21 Cowen
FedEx price target lowered to $283 from $297 at Cowen
09/23/21 Stifel
FedEx setup doesn't warrant 'trough valuation,' time to buy, says Stifel
09/23/21 Argus
FedEx price target lowered to $270 from $330 at Argus
09/23/21 Loop Capital
FedEx price target lowered to $324 from $381 at Loop Capital
FDX FedEx
$222.88 /

-1.32 (-0.59%)

FDX FedEx
$222.88 /

-1.32 (-0.59%)

FDX FedEx
$222.88 /

-1.32 (-0.59%)

FDX FedEx
$222.88 /

-1.32 (-0.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.